Highest-materiality recent filing
Aveanna completes $175.5M acquisition of Family First Homecare; raises FY2026 guidance
Completed acquisition of Family First Homecare for $175.5M cash, funded from cash on hand.
Aveanna Healthcare shareholders vote on three proposals at 2026 annual meeting
All three Class II director nominees elected: Windley ~150M for, 30M against; Weil ~160M for, 20M against; Rodgers ~168M for, 11M against.
Aveanna reprices $1.32B first lien debt, margin cut 50 bps; potential 25 bps more
Entered 13th amendment to first lien credit agreement; $1.318B term loans and $250M revolver repriced.
Aveanna provides May 2026 investor presentation; truncated exhibit limits detail
Aveanna released an investor presentation for May 2026.
Aveanna Q1 revenue up 15.9% to $647.9M; net income $41.7M vs $5.2M; raises FY guidance
Q1 revenue $647.9M (+15.9% YoY); net income $41.7M vs $5.2M in prior-year period.
Aveanna makes investor presentation available; no material new details provided
Company posted a financial presentation on March 20, 2026, available on its investor relations website.
Aveanna Q4 revenue $662.5M (+27.4% YoY); net income $178.8M; acquires Family First Homecare
Q4 revenue $662.5M (+27.4% YoY); net income $178.8M vs $29.2M prior year.
Aveanna to acquire Family First Homecare for $175.5M in cash, expands pediatric home care footprint
Purchase price of $175.5 million in cash, subject to working capital and other adjustments.
Aveanna director Robert M. Williams Jr. resigns effective February 27, 2026
Resignation from Class I director position effective immediately.
Aveanna Healthcare signs new employment pacts with Shaner, Buckhalter, Perchik
Jeff Shaner (CEO): base salary $750,000, target bonus 100%, severance 2x salary/bonus (non-CIC) or 2.5x (CIC).
Aveanna raises FY2025 revenue and EBITDA guidance; issues FY2026 outlook
FY2025 revenue guidance raised to ~$2.425-2.445B from >$2.375B.
Aveanna Healthcare director resigns, Bain's Sam Weil appointed; stockholder agreement amended
Christopher Gordon resigned as Class II director effective Nov 13, 2025; no disagreement with company.
Aveanna provides investor presentation; content not available in filing excerpt
Filed 8-K on November 7, 2025 under Item 7.01 furnishing an investor presentation.
Aveanna Q3 revenue up 22.2% to $621.9M; net income of $14.1M vs loss; raises FY guidance
Q3 revenue $621.9M (+22.2% YoY); net income $14.1M vs loss of $42.8M in prior year.
Selling stockholders (J.H. Whitney affiliates) sold 10,000,000 shares at $9.00 per share.
Aveanna Healthcare prelim Q3 revenue $616-624M, net income up ~130%
Revenue expected $616M-$624M, up ~21.0%-22.6% YoY.
Aveanna posts September 2025 investor presentation; content not disclosed in filing excerpt
Presentation furnished as Exhibit 99.1; no specific financial or operational updates detailed in the filing portion provided.
Aveanna completes $1.325B refinancing; extends maturities, repays $415M second lien debt
New $1.325B first lien term loans refinance $886M existing loans and add $439M incremental; maturity 2032 at SOFR+3.75%.
Aveanna furnishes August 2025 investor presentation without new material disclosures
Investor presentation dated August 2025 made available via SEC filing and company website.
Aveanna Q2 revenue $589.6M (+16.8% YoY); net income $27.0M; raises FY guidance
Q2 revenue $589.6M, up 16.8% YoY; net income $27.0M vs $13.9M.
Aveanna increases receivables financing facility to $275M and extends maturity by three years
Seventh Amendment to Receivables Financing Agreement raises maximum availability to $275.0 million.
Aveanna completes acquisition of Thrive Skilled Pediatric Care, issues 11.18M shares
Closed acquisition of Thrive SPC on June 2, 2025; issued 11,184,588 shares of common stock as merger consideration.
Aveanna furnishes May 2025 investor presentation; specific content not available
8-K filed May 9, 2025 under Item 7.01; presentation attached as Exhibit 99.1.
Aveanna stockholders elect three Class I directors; ratify auditor and approve say-on-pay
Victor Ganzi, Devin O'Reilly, and Robert M. Williams Jr. elected to three-year terms; each received >168M votes for, 3.8M–5.8M withheld, 8.7M broker non-votes.
Aveanna Q1: net income $5.2M vs loss; revenue +14% to $559.2M; raises FY25 guidance
Revenue $559.2M (+14.0% YoY); gross margin 32.8% vs 29.7%.
Aveanna to acquire Thrive Skilled Pediatric Care for ~$75M in stock and cash
Aveanna (AVAH) to acquire Thrive SPC for ~$75M, primarily in common stock, plus cash.
Director Sheldon Retchin resigns from Aveanna board for health reasons; no disagreement
Dr. Sheldon Retchin resigned from Board of Directors effective March 27, 2025 for personal health reasons.
Aveanna posts investor presentation; no material details disclosed
March 14, 2025: Aveanna Healthcare made available a financial presentation to investors (Exhibit 99.1).
Q4 revenue $519.9M (+8.6% YoY); gross margin $171.7M (33.0%) up 15.7%.
Aveanna Healthcare releases investor presentation for November 2024; no specific details available
Presentation filed as Exhibit 99.1 under Regulation FD; content not fully reproduced in this filing.
Aveanna Q3 revenue $509M (+6.5% YoY); Adj EBITDA $47.8M (+32.2%); raises FY24 guidance
Q3 revenue $509.0M, up 6.5% YoY; gross margin improved to 31.4% from 30.8%.
Aveanna appoints Brent Layton as Class III director and Audit Committee member
Brent Layton appointed to fill a Board vacancy effective November 1, 2024.
Tenth Amendment to First Lien Credit Agreement dated Sept 30, 2024 extends revolver maturity from Apr 2026 to Apr 2028.
Aveanna Healthcare makes investor presentation available; full content not provided in filing
Presentation released on August 9, 2024, but exhibit text is incomplete in this 8-K extract.
Aveanna Q2 revenue $505M (+7% YoY); Adj. EBITDA up 27.3%; raises FY guidance
Revenue $505M, up 7% YoY; gross margin $158.3M (+1.9%).
Aveanna Healthcare increases securitization facility to $225M via Fourth Amendment with PNC Bank
Maximum availability raised to $225.0 million, subject to borrowing base requirements.
Aveanna furnishes investor presentation for June 2024 conferences; no specific new details disclosed
Filing makes available a financial presentation for investor conferences and meetings.
Aveanna Healthcare shareholders elect three Class III directors, ratify EY, approve say-on-pay
Elected Sheldon M. Retchin, Erica G. Schwartz, and Jeff Shaner as Class III directors with ≥94% of votes cast.
Aveanna Healthcare provides investor presentation for May 2024 conferences
Presentation made available on May 10, 2024 for investor conferences and meetings.
Aveanna Q1 revenue $490.7M (+5.2%), net loss narrows to $11.2M; raises FY2024 guidance
Q1 revenue $490.7M (+5.2% YoY); gross margin $145.9M (29.7% of revenue).
Aveanna Q4 revenue up 6.1% to $478.8M; adjusted EBITDA +30.4%; FY2024 guidance issued
Q4 revenue $478.8M (+6.1% YoY), driven by Private Duty Services and Medical Solutions growth; Home Health & Hospice down slightly.
On March 27, 2025, and with immediate effect, Dr. Sheldon Retchin, a Class III Director of Aveanna Healthcare Holdings Inc., a Delaware corporation (the "Company"), notified the Company of his resignation from the Company's Board of Directors for personal health reasons.
On November 1, 2024, the Board of Directors (the “Board”) of Aveanna Healthcare Holdings Inc. (the “Company”) appointed Brent Layton to serve as a Class III director and as a member of the Audit Committee of the Board (the “Audit Committee”), to fill a vacancy.
Max materiality 0.85 · Median 0.50 · Most common event earnings